Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons

Marc Michel1,2,3,4, Maryam Heidary4, Anissa Mechri1,5

  • 1Inserm U934, CNRS UMR3215, Institut Curie, PSL Research University, Paris, France.

Abstract

Insights

A new method detects cancer DNA in blood by analyzing methylation patterns of long interspersed nuclear element-1 retrotransposons. This noninvasive approach shows high accuracy for detecting multiple cancer types, including early stages.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Circulating tumor DNA (ctDNA) enables noninvasive cancer profiling and monitoring.
  • Detecting low levels of ctDNA, especially during reduced tumor burden, remains a significant challenge.

Purpose of the Study:

  • To develop a highly sensitive strategy for detecting methylation patterns in plasma DNA.
  • To evaluate hypomethylation of long interspersed nuclear element-1 (LINE-1) retrotransposons as a multicancer biomarker.

Main Methods:

  • Implemented a novel method targeting 30-40,000 LINE-1 retrotransposons across ~100,000 CpG sites.
  • Utilized a reference-free analysis pipeline and machine learning classifiers.
  • Assessed copy number alterations for enhanced cancer detection.

Main Results:

  • Achieved high classification rates distinguishing healthy and tumor plasmas across six cancer types (colorectal, breast, lung, ovarian, gastric, uveal melanoma).
  • Demonstrated effectiveness in two independent cohorts with AUC values ranging from 88% to 100% (N = 747).
  • Included detection of localized cancer stages.

Conclusions:

  • The developed method shows potential for efficient, noninvasive diagnostic tests for cancer patients.
  • The universality of LINE-1 hypomethylation suggests broad applicability across various cancer types.
  • This approach could significantly advance individualized cancer management.